- Home
- GERN vs UTF Comparison
GERN vs UTF Comparison
Compare GERN & UTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- UTF
- Stock Information
- Founded
- GERN 1990
- UTF 2004
- Country
- GERN United States
- UTF United States
- Employees
- GERN N/A
- UTF N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- UTF Finance Companies
- Sector
- GERN Health Care
- UTF Finance
- Exchange
- GERN Nasdaq
- UTF Nasdaq
- Market Cap
- GERN 974.5M
- UTF N/A
- IPO Year
- GERN 1996
- UTF N/A
- Fundamental
- Price
- GERN $1.43
- UTF $27.05
- Analyst Decision
- GERN Buy
- UTF
- Analyst Count
- GERN 7
- UTF 0
- Target Price
- GERN $4.17
- UTF N/A
- AVG Volume (30 Days)
- GERN 9.7M
- UTF 171.7K
- Earning Date
- GERN 08-07-2025
- UTF 01-01-0001
- Dividend Yield
- GERN N/A
- UTF 7.19%
- EPS Growth
- GERN N/A
- UTF N/A
- EPS
- GERN N/A
- UTF 2.84
- Revenue
- GERN $116,293,000.00
- UTF $138,636,669.00
- Revenue This Year
- GERN $160.12
- UTF N/A
- Revenue Next Year
- GERN $55.01
- UTF N/A
- P/E Ratio
- GERN N/A
- UTF $9.16
- Revenue Growth
- GERN 22264.04
- UTF 19.80
- 52 Week Low
- GERN $1.17
- UTF $22.05
- 52 Week High
- GERN $5.06
- UTF $26.53
- Technical
- Relative Strength Index (RSI)
- GERN 46.80
- UTF 69.28
- Support Level
- GERN $1.34
- UTF $26.26
- Resistance Level
- GERN $1.57
- UTF $26.60
- Average True Range (ATR)
- GERN 0.10
- UTF 0.24
- MACD
- GERN -0.02
- UTF 0.06
- Stochastic Oscillator
- GERN 37.50
- UTF 91.18
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.